CN107375286A - Application of the trigonelline in the medicine for preparing external treatment echinococcosis granulosa - Google Patents
Application of the trigonelline in the medicine for preparing external treatment echinococcosis granulosa Download PDFInfo
- Publication number
- CN107375286A CN107375286A CN201710695296.7A CN201710695296A CN107375286A CN 107375286 A CN107375286 A CN 107375286A CN 201710695296 A CN201710695296 A CN 201710695296A CN 107375286 A CN107375286 A CN 107375286A
- Authority
- CN
- China
- Prior art keywords
- trigonelline
- protoscolex
- medicine
- days
- nrf2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses application of the trigonelline in the medicine for preparing external treatment echinococcosis granulosa, it is related to pharmaceutical technology field.The trigonelline of the present invention is used for the medicine for preparing external treatment echinococcosis granulosa, and the trigonelline is the extract of faenum graecum plant, smaller to side effect caused by the mankind.
Description
Technical field
The present invention relates to treatment echinococcosis granulosa technical field, more particularly to trigonelline to prepare external treatment particulate
Application in the medicine of hydatidosis.
Background technology
Trigonelline, the extract of legume faenum graecum, it can extensively extract and be compared less to the mankind from plant
Poisonous chemicals.Trigonelline is a kind of compound, is claimed always with anticancer, anti-migraine and norcholesterol and anti-sugar
Urine disease activity.Also have been reported that simultaneously, trigonelline is caused to the response to treatment of diabetes B rat by oral trigonelline
Serum insulin level declines.
Cystic echinococcosis (CE) is a global zoonosis, influences the larva rank of the mankind and domestic animal parasitism tapeworm
Echinococcus caused by section, it is a global public health and economic problems.If CE is treated not in time can cause sternly
The incidence of disease of weight and death.The main path of human infection parasite is oral cavity intake worm's ovum.Egg hatch is penetrated in intestines and stomach
Intestinal walls, into blood, and finally position mainly in liver and lung.At present, operation is maximally effective selection CE treatments, because
It reaches the condition of healing possibly through completely removing the cyst.But postoperative recurrence CE be due to tumour rupture or in hand
The leakage of tumour content during art, this is the complication echinococcosis of a main surgical operation.Therefore, using effective
Drug therapy is a part for an important surgical technic, helps to reduce the risk that protoscolex leaks in operation.
A kind of using medicine in surgical procedure is oral mode, and another is will in the case of exposure surgical field of view
The region that medicine is covered in protoscolex reduces its survival ability to kill protoscolex.But the existing medicine used,
Including saline solution, silver nitrate, cetrimonium bromide, ethanol.It is well known that the adverse reaction caused by echinococcosis is athero- including artery
Hardening, hepatonecrosis, hemiglobin disease etc..Therefore, it is badly in need of finding new safely and effectively medicine to treat echinococcosis granulosa,
And it can be used safely in surgical procedure.
The content of the invention
In view of this, the embodiments of the invention provide trigonelline in the medicine for preparing external treatment echinococcosis granulosa
Application, main purpose is to provide tumour content during one kind effectively can control and reduce operative treatment cystic echinococcosis and lets out
The pharmaceutical methods of leakage.
To reach above-mentioned purpose, invention broadly provides following technical scheme：
On the one hand, the embodiments of the invention provide trigonelline in the medicine for preparing external treatment echinococcosis granulosa
Using.
Preferably, the trigonelline is the extract of faenum graecum plant.
Preferably, the medicine is made up of the carrier and/or auxiliary agent of trigonelline and pharmaceutical acceptable.
The present invention handles the protoscolex of Echinococcus Granulosus Cysts using the trigonelline extract of various concentrations, passes through observation point
Analysis determines that trigonelline has following influence to above-mentioned protoscolex：
(1) positioning of Nrf2 in Echinococcus Granulosus Cysts is influenceed using trigonelline in vitro；
(2) NQO-1 and HO-1 activity is influenceed using trigonelline in vitro；
(research is by inducing Nrf2 dependent responses (including the use of antioxidant and detoxication enzyme) to prevent in cell
Caused oxidative damage.For example, HO-1 and NQO-1 expression can be adjusted by Nrf2, it is special in Nrf2 signal paths
The antioxidase of property.HO-1 and NQO-1 has genetic transcription as the regulation of antioxidase and II type detoxication enzyme to Nrf2-ARE
With the function of expression, while can strengthen vivo oxidation stress resistance and body defence protective capability.HO-1 and NQO-1
Be induction stress, anoxic, endotoxin, heat shock, heavy metal, hemoglobin, the initial enzyme of cell factor and antioxidant etc., this
A little factors can induce the expression of HO-1 and NQO-1 activity.HO-1 and NQO-1 systems participate in many physiology and the tune of pathologic process
Section, HO-1 and NQO-1 expression rises can increase the oxidation resistance of human body, reduce oxidative damage.)
(3) form of Echinococcus Granulosus Cysts protoscolex is influenceed using trigonelline in vitro；
(4) vigor of Echinococcus Granulosus Cysts protoscolex is influenceed using trigonelline in vitro；
(5) structure of Echinococcus Granulosus Cysts protoscolex is influenceed using trigonelline in vitro；
(6) in vitro using trigonelline induction Caspase apoptosis.(Caspase：Caspase is aspartic acid
A part for specific cysteine protease family, its by various stimulations for example oxidative stress adjust Apoptosis and
Played an important role in apoptosis-induced.An important factor for Caspase-3 is in apoptotic process, its energy in proteolytic activations
It is enough to be further activated).
Compared with prior art, the beneficial effects of the invention are as follows：
The present invention effectively can not control and reduce tumour content during operative treatment cystic echinococcosis for conventional medicament
The technical problem of thing leakage, is led to by studying Nrf2 protein expressions in Echinococcus Granulosus Cysts protoscolex, trigonelline in Nrf2 signals
The depression effect and Nrf2 signal paths on road suppress the influence of Echinococcus Granulosus Cysts, employ and are transcribed trigonelline as Nrf2
Factor inhibitors and the technological means that can be controlled in vitro to Echinococcus Granulosus Cysts protoscolex, and trigonelline carries for plant
Thing is taken, smaller to mankind's side effect with respect to other drugs, Echinococcus Granulosus Cysts can effectively be suppressed and then can answer by having reached trigonelline
Technique effect for the medicine of external treatment echinococcosis granulosa.
Brief description of the drawings：
Fig. 1 is the Immunofluorescent localization of Nrf2 albumen and the effect of expression in the Echinococcus Granulosus Cysts that the embodiment of the present invention 1 provides
Fruit schemes (A:Nrf2 untreated fish groups show green florescent signal, B:Nucleus display is red to represent signal, C:It is present in after mixing
In cytoplasm)；
Fig. 2 is the immunofluorescence that the trigonelline that the embodiment of the present invention 1 provides acts on Nrf2 albumen in Echinococcus Granulosus Cysts
Positioning and the design sketch (A-C of expression：Nrf2 antibody is replaced using PBS；D-F:Control group；G-I：Protoscolex uses trigonelline
It is incubated, concentration is 100 μm of ol/L36 hours；J-L:Protoscolex is incubated using trigonelline, and concentration is 200 μm of ol/L36 hours)；
Fig. 3 is that the trigonelline that the embodiment of the present invention 1 provides acts on protoscolex 3 days and the HO-1 activity columns after 6 days
Scheme (Bar graph indicates：* compared with control group, P<0.05；Compare between # groups, P<0.05)；
Fig. 4 is that the trigonelline that the embodiment of the present invention 1 provides acts on protoscolex 3 days and the NQO-1 activity columns after 6 days
Figure
(Bar graph indicates：* compared with control group, P<0.05；Compare between # groups, P<0.05)；
Fig. 5 be the embodiment of the present invention 1 provide protoscolex by trigonelline processing after with control group metamorphosis
Light microscopic figure (A：Control group, B：Protoscolex treatment group, C：Handled 6 days using 100 μm of ol/L, D：12 are handled using 100 μm of ol/L
My god, E：Handled 6 days using 250 μm of ol/L, F：Handled 12 days using 250 μm of ol/L)；
Fig. 6 is that the Echinococcus Granulosus Cysts that the embodiment of the present invention 1 provides are bent using the vigor after the effect of various concentrations trigonelline
Line chart；
Fig. 7 is that the protoscolex that the embodiment of the present invention 1 provides uses the structure electron microscope after the effect of various concentrations trigonelline
(A：Control group, B：DMSO treatment groups, C：100 μm of ol/L are handled 2 days, D:100 μm of ol/L are handled 6 days, E:200 μm of ol/L processing 2
My god, F:200 μm of ol/L are handled 6 days)；
Fig. 8 be the embodiment of the present invention 1 provide protoscolex through trigonelline handle 24 hours and 48 hours after caspase-3
Active block diagram (Bar graph indicates：* compared with control group, P<0.05；Handled between # groups, P<0.05).
Embodiment
Be further illustrate the present invention to reach the technological means and effect that predetermined goal of the invention is taken, below with compared with
Good embodiment, to embodiment, technical scheme, feature and its effect according to the present patent application, describe in detail as after.Under
State it is bright in multiple embodiments in special characteristic, structure or feature can be combined by any suitable form.
Embodiment 1
Prepare material：Nrf2 antibody is purchased from Sheng Keluzi, and trigonelline is available from Sigma Aldrich (St, Louis
This, the Missouri State, the U.S.), trigonelline is dissolved in concentration as 10-1It is (public purchased from Suo Laibao in mol/L dimethyl sulfoxides (DMSO)
Department), based on the preliminary result initially carried out, the concentration for extracting trigonelline is diluted according to corresponding dosage, and is needed
Want Fresh, matching while using, preparing completion needs filtration sterilization to use, and the culture mediums of RPMI 1640 are purchased from Sigma, HO-1 and
NQO-1 testing equipments are purchased from the excellent Er Sheng experimental facilities company in Wuhan.
Collect and cultivate protoscolex：Echinococcus Granulosus Cysts are extracted from the liver of slaughtered sheep and goat and are collected, and are infected
After liver surface sterilization, the Hydatid fluid of collection is put into and is contained with containing antibiotic (100U/ milliliters pencillin and 100U/ milli
Rise streptomysin) sterile saline container in stand 30 minutes；The protoscolex of Echinococcus Granulosus Cysts is deposited on said vesse
Bottom, supernatant liquor is abandoned, select and remain container bottom deposit and centrifuged using centrifuge tube；Before culture and infection, using PBS
(pH value 7.2) is rinsed 3-5 times to the protoscolex of above-mentioned deposition；Culture supplements 10% tire ox blood in the culture mediums of RPMI 1640
Clearly, and in 37 DEG C, 5% CO2gas incubator it is incubated, above-mentioned culture medium changes liquid once in every 3 days；Each feasibility is real
Test in triplicate；Coloration experiment is carried out using 0.1% Yihong, observes that the existence of above-mentioned protoscolex is lived under an optical microscope
Power is at least more than 98%.
Drug therapy：Above-mentioned flushed protoscolex is mixed with the culture mediums of RPMI 1640, adds faenum graecum thereto
Alkali, the concentration of the above-mentioned trigonelline medicine of addition is respectively the (concentration unit of 50,100,150,200 and 250：μm ol/L), shape
Into five experimental groups, trigonelline medicine is not added with control group；
500 μ L protoscolex deposit is added among 4.5mL culture medium, at the same time, trigonelline added
Into six orifice plates of equal densities, control group is blank control, and the concentration of experimental group is followed successively by 50,100,150,200 and 250
(concentration unit：μm ol/L), the total capacity of each six orifice plate is 5mL, including 500 μ L protoscolex suspension, this 500
2000 to 2500 protoscolexs are added in every hole respectively by counting in μ L protoscolex suspension, now each hole raffinate
The scale of construction should add 4500 μ L, and according to the concentration order of experimental group setting, each group adds the agent of the trigonelline prepared
Amount is respectively：0/25/50/75/100/125 μ L, the dosage of corresponding addition culture medium are：4500/4475/4450/4425/
4400/4375μL)；Changed in experimentation using the mode of appearance of the above-mentioned each group protoscolex of micro- sem observation, by 6-12
After its treatment, sample after collection treatment, and carry out SEM (SEM) observation.
Fluoroimmunoassay：Protoscolex sample is rinsed 3-5 times using PBS (pH value 7.2), and fixes and stores in paraformaldehyde
Deposit 36 hours；The concentration for embedding trigonelline sample is 100 μm of ol/L and 200 μm of ol/L, using 1.5% Agarose embedding
The protoscolex treated with various concentrations trigonelline, fixed after processing in 6-12 days using 4% paraformaldehyde after sample then at 4 DEG C
Preserve；It is fixed according to tissue paraffin permeating and dewatering, FFPE, paraffin section；Antigen is repaired using citric acid, with quality point
Number is 10 minutes after the section of 3% hydrogen peroxide sealed sample, is then rinsed 3 times with PBS solution, 5 minutes every time, it was unnecessary to remove
PBS, nrf2 antibody, general 50 μ L are added to the sample surfaces on slide, then be put into black box and stayed overnight at 4 DEG C；Will after second day
To on slide sample surfaces rinse 3 times again into the sample surfaces on slide add FITC mark fluorescence antibody,
1h is cultivated at 37 DEG C, then (50 μ g/mL dye solution, lucifuge dye 3 minutes for addition；Finally, it is (immune glimmering in FCFM scannings
Ray laser scanning confocal microscope) under observed.
Measure HO-1 and NQO-1 activity：It is 100 μm of ol/L and 200 μm of ol/L that protoscolex sample is individually placed into concentration
Handled, handled 6-12 days in trigonelline；After treatment processing, protoscolex pyrolysis product RIPA and PMSF, (RIPA are collected：
It is a kind of traditional cell tissue rapid cleavage liquid.The protein sample that RIPA lysates crack to obtain can be used for conventional
Western, IP etc..PMSF：For protease inhibitors, can suppress serine protease (such as trypsase, chymotrypsin,
Fibrin ferment) and thiol protease (such as papain))；Using centrifuge to homogenate (the protoscolex suspension after cracking) centrifugation
Twice, first time centrifugal condition is 5000g × 5 minute, 4 DEG C, obtained supernatant liquor, then homogenate is carried out into second and centrifuged,
Centrifugal condition is 12000g × 10 minute, 4 DEG C of centrifuges；Supernatant twice is collected, then by supernatant and kit
In reaction reagent at 37 DEG C, hatch 60 minutes and is incubated in dark, reuse 50uL terminate liquid termination；
The optical density of HO-1 and NQO-1 activities is calculated by measuring absorbance, and the absorbance of the ELISA Plate used exists
450nm, test three times at random and take its average value.
Viability examination：The viability examination of protoscolex is to use 0.1% (1 gram of Yihong powder dissolves in 1000 milliliters of distilled water)
Eosin stain is observed under an optical microscope；The protoscolex for not absorbing dyestuff is considered as possible survival, otherwise, record
To be dead；Observe result.
Electron microscope：Protoscolex sample is used into trigonelline culture in vitro, the concentration of trigonelline is respectively 100
μm ol/L and 200 μm of ol/L concentration, after having handled 6-12 days, protoscolex sample is rinsed 3-5 times, and various concentrations will have been used
The treated protoscolex of trigonelline fixes storage 36 hours in paraformaldehyde, then at 4 DEG C of preservations；Finally, using LE01430VP
SEM is in protoscolex sample of the 20KV observation analysis through trigonelline culture.
Measure caspase-3 activity：Using caspase-3 colorimetric assay kits to caspase-3 enzymes in protoscolex
Activity is detected；Respectively using various concentrations trigonelline (50,100,150,200 and 250, concentration unit：μmol/L)
24 hours and 48 hours are acted on protoscolex sample respectively, extract the cytoplasmic protein supernatant after 3 milligrams of cracking, and added
Into analysis buffer, protoscolex pyrolysis product and the specific substrate of caspase are contained in analysis buffer
(caspase-3Ac-DEVD-ρNA)；
Cytoplasmic protein supernatant, protoscolex pyrolysis product and the specific substrate (caspase-3Ac-DEVD- of caspase
ρ NA) mixture 96 orifice plates hatch 4-6h, 37 DEG C, absorbance measurement 405nm；Caspase-3 activity expressions pass through
OD405Absorbance reaction, control group only includes reaction buffer and substrate；Observe caspase-3 activity.
Statistical analysis：Above-mentioned experiment repeats three times；Data analysis is to use SPSS statistical packages version 2 0.0；
Difference between test group and control group carries out analysis and passes through ± SDs；Also t is examined, One-way ANOVA and LSD P<0.05,
With statistical significance.
Analysis below is carried out according to the above-mentioned experimental result of the present invention：
The interaction in vitro of trigonelline influences the positioning of Nrf2 in Echinococcus Granulosus Cysts：Immunofluorescence test protoscolex uses calabash
Reed bar alkali has carried out processing and undressed control group；Nrf2 is in untreated fish group, and display green florescent signal is (referring in Fig. 1
A), nucleus, show it is red represent signal (referring to the B in Fig. 1), find to be primarily present in cytoplasm (ginseng after mixing
The C seen in Fig. 1)；
There is no green fluorescence expression (referring to the A-C in Fig. 2) by Nrf2 antibody hatching untreated fish group；By contrast, sample
Product show that Nrf2 expression is gradually decreased (referring to the D/E/F/ in Fig. 2 through ol/L and 200 μm of ol/L of trigonelline treatment group 100 μm
G/J)；This signal discovery is still mainly among kytoplasm (F in Fig. 2, L)；Nrf2 expression is in 100mol/L treatment groups (figure
G, H, I in 2) it is higher than 200 μm of ol/L treatment groups (J in Fig. 2, K, L) 36h.
Activity of the vitro detection trigonelline to NQO-1 and HO-1：Analyzed using colorimetric method, in trigonelline
Act on protoscolex 3 days or 6 days concentration is respectively the obvious change of appearance under conditions of 100 μm of ol/L and 200 μm of ol/L.
(HO) -1 has concentration dependent with (NQO) -1 activity, and at the same time antioxidation activity was less than 3 days at 6 days；These data are said
It is related to (HO) -1 and (NQO) -1 path that bright trigonelline acts on protoscolex, as shown in Figure 3 and Figure 4.
Trigonelline interaction in vitro is in the morphological observation of Echinococcus Granulosus Cysts protoscolex：The metamorphosis research pin of protoscolex
Observed to the trigonelline using various concentrations and using inverted microscope；The protoscolex for the treatment of group caves inward, and has good
Movable and complete spherical or oval polypide structure, internal structure is complete, has obvious visual calcium particle (such as Fig. 5 institutes
Show)；
Dimethyl sulfoxide (DMSO) control group is in whole experimental period as negative control (B in such as Fig. 5)；Trigonelline is made
Protoscolex for being survived after protoscolex is refused to contaminate, and dead protoscolex absorbs Yihong and dyes red；Protoscolex was in culture 12 days
Vigor substantially weakens afterwards；Particularly 250 μm of ol/L trigonellines of protoscolex processing (D in such as Fig. 5), 100 μm of ol/ of ratio after 6 days
L trigonellines vigor weakens (as shown in the C in Fig. 5)；Protoscolex enhances vigour decrease over time, until survival ability about
It is 12 days 250 μm of ol/L groups (as shown in the F in Fig. 5), although 100 μm of ol/L for the treatment of group trigonelline show that curative effect reduces,
The protoscolex for still having 50% is survived (as shown in the E in Fig. 5)；Protoscolex form generation substantially changes after being handled by trigonelline
Become and internal structure produces change；Above-mentioned experiment clearly illustrates that the dosage of trigonelline and time have cause to protoscolex
The effect of life.
Use influence of the trigonelline to Echinococcus Granulosus Cysts protoscolex vigor in vitro：Referring to Fig. 6, respectively using various concentrations
Trigonelline act on protoscolex (50,100,150,200, and 250, unit：μmol/L)；In drug-treated group and control group
Contrasted, the vigor of blank group does not change significantly, and survival rate is still 91% after changing 12 days over time；100μ
Mol/L and 200 μm of ol/L protoscolex is acted on 6 days using trigonelline, and survival rate was respectively 79.2% and 72.5%, at 12 days
When be further decreased to 56% and 31%, particularly, protoscolex is whole after 250 μm of ol/L of trigonelline maximum concentration are acted on 12 days
It is dead.Therefore, Echinococcus Granulosus Cysts protoscolex has dosage and time dependence to trigonelline.
In vitro using trigonelline to the performance under Echinococcus Granulosus Cysts protoscolex ultra micro Electronic Speculum：Referring to Fig. 7, at trigonelline
Ultrastructural change after reason protoscolex mainly uses ESEM；Blank group does not have the change of obvious tissue hyper-microstructure
(as shown in the A in Fig. 7), protoscolex cephalomere after DMSO cultures turn up (referring to the B in Fig. 7).But observation morphology
Damage with ultra microstructure is in drug-treated group.Morphologic change is 100 μm of ol/L trigonellines treatment group ratios at 6 days
More apparent (referring to the C in Fig. 7).By 12 days 100 μm of ol/L processing of trigonelline, it is observed that processus coracoideus disintegrates and polypide
Surface indentation；In addition, also damage by worms shape lesion exist (referring to the E in Fig. 7)；By 6 days 200 μm of ol/L treatment group, sweep
The presence of Electronic Speculum display surface change, the deformation of head hook are retouched, polypide is collapsed, and processus coracoideus is disintegrated (referring to the D in Fig. 7)；Pass through 200 μ
Mol/L trigonellines are handled 12 days, and sucker deformation, microtriche comes off, and observe that protoscolex has serious digitation and worm
The lesion of moth (referring to the F in Fig. 7).
The external evoked Caspase of trigonelline apoptosis：The above-mentioned experimental study caspase protein enzyme of the present invention
Activation, this is a key enzyme of inducing cell apoptosis；The above-mentioned experiment of the present invention measures caspase-3 activity, uses
Caspase-3 kits AcDEVD- ρ NA are as standard, trigonelline processing 24h or 48h of the protoscolex Jing Guo various concentration；With
Afterwards, present invention discover that trigonelline processing 24h and 48h respective concentration can significantly affect caspase-3 activity；In addition,
In protoscolex caspase-3 activity after drug-treated 48 hours apparently higher than 24 hours (P<0.05), as shown in Figure 8.
The present invention it is above-mentioned test result indicates that, Nrf2 is mainly expressed in cytoplasm in protoscolex.The research of the present invention
As a result further display, Nrf2 protein levels reduce after trigonelline treats Echinococcus Granulosus Cysts.Actually, the present invention is also sent out
Existing, Nrf2 is less than 100 μm of ol/L treatment groups in 200 μm of ol/L concentration trigonellines treatment group expression (time is 36h).More than
Confirm that trigonelline lowers Nrf2 in cytoplasmic expression and has dose dependent.
The present invention it is above-mentioned test result indicates that, the influence of dose-dependent correlation to trigonelline be present in protoscolex,
All dead behind 12 days by 250 μm of ol/L trigonelline processing of protoscolex, the death rate reaches 100%, substantially exceeds 50,
100th, the dosage of 150 and 200 μm of ol/L trigonelline.
The present invention it is above-mentioned test result indicates that：The Dynamic Curve and light microscopic figure of experiment show protoscolex structure confusion.Make
With scanning electron microscopic observation, the inventors discovered that protoscolex treats 6 days 250 μm of ol/L using trigonelline loses a hook-type state, inhale
Disk deforms, and digitation and the lesion damaged by worms；Conversely, normal form and ultra microstructure is presented in protoscolex control group.
The present invention it is above-mentioned test result indicates that：Immunofluorescence confirms the Nrf2 mainly tables in the cytoplasm of protoscolex
Reach.The expression of Nrf2 signal paths suppresses to play key effect in protoscolex existence in trigonelline；Trigonelline is to prove
Heavy damage and existence obstacle are induced in protoscolex, this is due to the regulation of HO-1 and NQO-1 activity；Therefore, it is of the invention upper
State experimental result to show, trigonelline can be as the medicine of external treatment echinococcosis granulosa.
Part, those skilled in the art can not select from the prior art to the greatest extent in the embodiment of the present invention.
Disclosed above is only the embodiment of the present invention, but protection scope of the present invention is not limited thereto, and is appointed
What those familiar with the art the invention discloses technical scope in, change or replacement can be readily occurred in, all should
It is included within the scope of the present invention.Therefore, protection scope of the present invention should using above-mentioned scope of the claims as
It is accurate.
Claims (3)
1. application of the trigonelline in the medicine for preparing external treatment echinococcosis granulosa.
2. application of the trigonelline according to claim 1 in the medicine for preparing external treatment echinococcosis granulosa, its
It is characterised by, the trigonelline is the extract of faenum graecum plant.
3. application of the trigonelline according to claim 1 in the medicine for preparing external treatment echinococcosis granulosa, its
It is characterised by, the medicine is made up of the carrier and/or auxiliary agent of trigonelline and pharmaceutical acceptable.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710695296.7A CN107375286A (en) | 2017-08-15 | 2017-08-15 | Application of the trigonelline in the medicine for preparing external treatment echinococcosis granulosa |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710695296.7A CN107375286A (en) | 2017-08-15 | 2017-08-15 | Application of the trigonelline in the medicine for preparing external treatment echinococcosis granulosa |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107375286A true CN107375286A (en) | 2017-11-24 |
Family
ID=60355730
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710695296.7A Pending CN107375286A (en) | 2017-08-15 | 2017-08-15 | Application of the trigonelline in the medicine for preparing external treatment echinococcosis granulosa |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107375286A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113262222A (en) * | 2021-04-14 | 2021-08-17 | 天津中医药大学 | Application of trigonelline in preparation of medicine for preventing and/or treating diabetic cardiomyopathy |
-
2017
- 2017-08-15 CN CN201710695296.7A patent/CN107375286A/en active Pending
Non-Patent Citations (1)
| Title |
|---|
| WENJUAN QIN等: ""Effects of trigonelline inhibition of the Nrf2 transcription factor in vitro on Echinococcus granulosu", 《ACTA BIOCHIM BIOPHYS SIN》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113262222A (en) * | 2021-04-14 | 2021-08-17 | 天津中医药大学 | Application of trigonelline in preparation of medicine for preventing and/or treating diabetic cardiomyopathy |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108309962A (en) | A kind of application of compound in terms of inhibiting amyloid protein to build up treatment senile dementia | |
| EP3835413A1 (en) | Method and composition for promoting cell growth and tissue repair | |
| CN106038597A (en) | Application of mesenchyma stem cells to preparation of acute lung injury treating preparation | |
| CN112156100A (en) | Application of salidroside in preparation of medicine for preventing and treating cardiovascular diseases caused by injury of coronary artery endothelial cells | |
| CN104357445B (en) | Interfering RNA for inhibiting and treating echinococcus granulosus disease and application thereof | |
| CN107249600A (en) | Novel pharmaceutical composition and its purposes for treating injury of lungs | |
| CN107375286A (en) | Application of the trigonelline in the medicine for preparing external treatment echinococcosis granulosa | |
| CN109954002A (en) | Application of the human umbilical cord mesenchymal stem cells in preparation prevention Parkinson's disease or the drug for treating Early Parkinson's disease | |
| CN106491652A (en) | Goose eggembryosin preparation method and application | |
| CN106562994A (en) | Preparation method for preparing duck embryos and application of duck embryos | |
| Yuan et al. | Gamma‐Ray Treatment of Echinococcus Protoscoleces prior to Implantation in Mice Reduces Echinococcosis | |
| CN105030952B (en) | A kind of composition is preparing the application in preventing urinary calculus drug | |
| Hamad | The effect of aqueous and alcoholic extract of nerium oleander on biochemical parameters of rats infected with echinococcus granulosus | |
| CN106562995A (en) | Preparation method for preparing swan embryos and application of swan embryos | |
| JPWO2003018058A1 (en) | Cardiomyocyte apoptosis inhibitor | |
| Margo et al. | Subacute zygomycosis of the orbit | |
| Menon et al. | Tissue reactions to Cysticercus cellulosae in man | |
| CN114948941B (en) | New application of artemisinin and pharmaceutical composition | |
| CN109985049A (en) | Application of -3 beta, 5,6 beta-triol of 5 α-androstane in the drug of preparation treatment cerebral small vessels disease | |
| CN114560817B (en) | Small molecule drug for inhibiting fibrosis and application thereof | |
| CN110755416B (en) | Application of loureirin A in preparing medicine for preventing or treating diabetic angiopathy | |
| CN107693509A (en) | SB FI 26 are preparing the application in treating breast cancer medicines | |
| US6177106B1 (en) | Method for fractionating red blood cells and antibacterial materials for bacterial proliferation inhibitors produced thereby | |
| CN106038531A (en) | Application of chlorogenic acid to induction of HepG2 cell apoptosis | |
| CN115902241A (en) | Application of vimentin in preparation of drug for treating angiostrongylus cantonensis disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20171124 |
|
| RJ01 | Rejection of invention patent application after publication |